Literature DB >> 6092407

Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion.

T H Schürmeyer, P C Avgerinos, P W Gold, W T Gallucci, T P Tomai, G B Cutler, D L Loriaux, G P Chrousos.   

Abstract

The responses of plasma immunoreactive ACTH (IR-ACTH), cortisol, GH, PRL, and LH to a single iv injection of 0.01-5 micrograms/kg human corticotropin-releasing factor (hCRF) were investigated in healthy volunteers. The lowest effective dose of hCRF was 0.5 micrograms/kg. hCRF caused brief pulse-like elevations of plasma IR-ACTH and cortisol without any effect on the plasma concentrations of GH, PRL, and LH. By contrast, ovine CRF (oCRF), given for comparison, produced long-lasting stimulation of the human pituitary-adrenal axis. The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man. No serious side effects occurred at any of the doses of hCRF tested. The highest dose (5 micrograms/kg) caused a slight increase of heart rate that was not associated with significant changes in arterial blood pressure. All subjects receiving 5 micrograms/kg and one third of the subjects receiving 1 micrograms/kg hCRF experienced a transient facial flush. We conclude that hCRF causes brief plasma ACTH and cortisol secretory episodes in man, similar to the physiological plasma ACTH and cortisol secretory episodes. This is in contrast to oCRF, which causes prolonged ACTH and cortisol secretion. These differences between the two peptides may be explained by the higher MCR of hCRF than oCRF.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092407     DOI: 10.1210/jcem-59-6-1103

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  [The necessity for perioperative cortisol substitution. Spontaneous and stimulated ACTH and cortisol secretion during unilateral adrenalectomy for renal cell carcinoma].

Authors:  P Bischoff; J Noldus; J Harksen; H W Bause
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 2.  Safety and side effects of human and ovine corticotropin-releasing hormone administration in man.

Authors:  M Nink; U Krause; H Lehnert; J Beyer
Journal:  Klin Wochenschr       Date:  1991-03-18

3.  Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.

Authors:  L A Frohman; T R Downs; T C Williams; E P Heimer; Y C Pan; A M Felix
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications.

Authors:  H M Schulte; G P Chrousos; P W Gold; J D Booth; E H Oldfield; G B Cutler; D L Loriaux
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

6.  Ambulatory assessments of psychological and peripheral stress-markers predict birth outcomes in teen pregnancy.

Authors:  Julie Spicer; Elizabeth Werner; Yihong Zhao; Chien Wen Choi; Sara Lopez-Pintado; Tianshu Feng; Margaret Altemus; Cynthia Gyamfi; Catherine Monk
Journal:  J Psychosom Res       Date:  2013-08-13       Impact factor: 3.006

7.  Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans.

Authors:  A Sasaki; O Shinkawa; K Yoshinaga
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 8.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

9.  Limited clinical usefulness of plasma corticotropin-releasing hormone, adrenocorticotropin and beta-endorphin measurements as markers of lung cancer.

Authors:  A E Calogero; G Minacapilli; A M Nicolosi; M L Moncada; A Mistretta; S F Latteri; P Polosa; R D'Agata
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

10.  Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone.

Authors:  A Kübler; G Rothacher; V A Knappertz; G Krämer; M Nink; J Beyer; H Lehnert
Journal:  Clin Investig       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.